Form 4: TriSalus Life Sciences CFO James Emmett Young Reports Acquisition of 14,762 Shares of Common Stock
SEC Form 4 Filing
James Emmett Young, CFO of TriSalus Life Sciences, reports the acquisition of 14,762 shares of common stock and the disposal of 30,000 shares held indirectly through a trust.
Summary
- On February 18, 2025, James Emmett Young, the Chief Financial Officer of TriSalus Life Sciences, acquired 14,762 shares of common stock.
- These shares were granted as restricted stock units (RSU Award) at a price of $0.
- The reporting person also disposed of 30,000 shares held indirectly by Kathleen A. Young Living Trust.
- The RSU Award vests in installments: 12.5% on the grant date (February 18, 2025), 25% on May 15, 2025, August 15, 2025, and November 14, 2025, and the remaining shares on February 13, 2026, contingent upon continued service with the Issuer.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options to the CFO is a positive sign, aligning his interests with shareholders. The disposal of shares from the trust is not necessarily negative, as it could be for estate planning or diversification purposes.
Positives
- The grant of restricted stock units to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages continued service with the company.
Future Outlook
The vesting schedule of the RSU award extends to February 13, 2026, contingent on the Reporting Person's continued service.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of shares by the CFO could be viewed positively by shareholders, as it demonstrates confidence in the company's future.
- The vesting schedule of the RSU award incentivizes the CFO to remain with the company, providing stability.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of transaction: Acquisition of 14,762 shares of common stock and grant date of restricted stock units; 12.5% of RSU Award vests. |
| 02/18/2025 | Date of transaction: Disposal of 30,000 shares held indirectly by Kathleen A. Young Living Trust. |
| 05/15/2025 | 25% of the shares subject to the RSU Award shall vest. |
| 08/15/2025 | 25% of the shares subject to the RSU Award shall vest. |
| 11/14/2025 | 25% of the shares subject to the RSU Award shall vest. |
| 02/13/2026 | Remaining shares subject to the RSU Award will vest. |
| 02/19/2025 | Date of signature. |
Keywords
TriSalus Life Sciences, James Emmett Young, CFO, Form 4, Beneficial Ownership, Restricted Stock Units, Common Stock, Kathleen A. Young Living Trust, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.